Skip to content

Three Quick Facts: Dalata Hotels, PureTech, Bigblu Broadband


Three things you need to know in the financial markets today from investment writer, Tony Cross.

Dalata Hotels sees H1 revenues add 29%

Dalata Hotels [LON:DHG], Ireland’s largest hotel operator, has this morning issued interim results, noting revenues for the first half of the year are up 29% and adjusted EBITDA is up 24%. The useful RevPAR (revenue per available room) metric added 23% and the company continues to grow its property portfolio, notably in the UK. However against these strong numbers, pre-tax profits are down 3%, but with RevPAR expected to keep growing and improved cost control, the impact here may be short lived.

PureTech hints at better shareholder payouts

PureTech Health [LON:PRTC] has half year numbers out, noting that key clinical and financial milestones had been achieved. The company has solid cash reserves of $350m, whilst operating expenses for the last six months stood at just under $80m. However the key lure for investors may be the promise of a more robust capital return strategy off the back of the performance of portfolio companies.

Bigblu Broadband revenues flat year-on-year

Bigblu Broadband [LON:BBB] has issued interims to 31st May. Revenues are broadly flat but EBITDA growth is a robust 21%, numbers which are seen as being in line with management expectations. Geographically, the focus for growth appears to be in Australia following successful acquisitions made there, with management ready to consider further purchase opportunities as they arise.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top